Bivatuzumab (Anti-CD44v6)
Synonyms: BIWA 4; Anti-CD44 Recombinant Antibody
Bivatuzumab (Anti-CD44v6) is a humanised monoclonal antibody targeting against CD44v6 that could acts as a sarcoma target for CAR-redirected CIK cells. MW:145.5 KD.
Quality Control
Mechanism of Action
| Description |
Bivatuzumab (Anti-CD44v6) is a humanised monoclonal antibody targeting against CD44v6 that could acts as a sarcoma target for CAR-redirected CIK cells. MW:145.5 KD.
|
|---|
Product Details
| CAS No. | 214559-60-1 |
|---|---|
| Molecular Weight | 145.5 kDa |
| Isotype | Human IgG1 |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage | Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
Comparison of Clones for
*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)
Tech Support
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.